The team of Marios Georgakis used an IL6 genetic instrument to mimic IL-6 inhibition in over 500,000 individuals, showing reduced risks of coronary and peripheral artery disease and ischemic stroke without infection concerns— lowering pneumonia hospitalizations—supporting IL-6 inhibitors under development in ongoing cardiovascular trials.